DrugPatentWatch Database Preview
TACE Drug Profile
or, see our see our flat-rate plans
When do Tace patents expire, and what generic alternatives are available?
The generic ingredient in TACE is chlorotrianisene. There are four drug master file entries for this compound. Additional details are available on the chlorotrianisene profile page.
Summary for TACE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Bulk Api Vendors: | 33 |
| Patent Applications: | 4,106 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | TACE at DailyMed |
Medical Subject Heading (MeSH) Categories for TACE
Synonyms for TACE
| 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene |
| 1-[2-chloro-1,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene |
| 1-[2-Chloro-1,2-bis(4-methoxyphenyl)vinyl]-4-methoxybenzene # |
| 1,1',1''-(1-Chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene) |
| 1,1',1''-(2-chloroethene-1,1,2-triyl)tris(4-methoxybenzene) |
| 1,1',1''-(2-chloroethene-1,1,2-triyl)tris[4-(methyloxy)benzene] |
| 1,1',1''(1-Chloro-1-ethenyl-2-ylidene)tris[4-methoxybenzene] |
| 162370-EP2280006A1 |
| 162370-EP2281813A1 |
| 4-06-00-07650 (Beilstein Handbook Reference) |
| 4,4',4''-(2-chloroethene-1,1,2-triyl)tris(methoxybenzene) |
| 569-57-3 |
| 569C573 |
| 6V5034L121 |
| AB00051941 |
| AC-12512 |
| AC1L1X1E |
| AC1Q3FDW |
| AKOS015960863 |
| Anisene |
| API0001964 |
| B5912 |
| BC204747 |
| Benzene, 1,1',1'-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy)- |
| Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy- |
| Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy)- |
| Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy- |
| Benzene,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy- |
| BFPSDSIWYFKGBC-UHFFFAOYSA-N |
| BPBio1_000852 |
| BRN 1891845 |
| BSPBio_000774 |
| BSPBio_002005 |
| C-50387 |
| CAS-569-57-3 |
| CCG-40079 |
| CCRIS 4769 |
| CHEBI:3641 |
| CHEMBL1200761 |
| Chloortrianisestrol |
| Chlorestrolo |
| chlorotrianisene |
| Chlorotrianisene (INN) |
| Chlorotrianisene [BAN:INN] |
| Chlorotrianisene [INN:BAN] |
| Chlorotrianisene [Nonsteroidal oestrogens] |
| CHLOROTRIANISENE CRYSTALLINE |
| Chlorotrianisene, ~95% |
| Chlorotrianisenum |
| Chlorotrianisenum [INN-Latin] |
| chlorotrianisestrol |
| Chlorotrianisine |
| Chlorotrianizen |
| Chlorotris(p-methoxyphenyl)ethylene |
| Chlorotrisin |
| Chlortrianisen |
| Chlortrianisene |
| Chlortrianisenum |
| Chlortrianisestrol |
| Chlortrianisoestrolum |
| Chlortrianizen |
| CJ-23983 |
| Clorestrolo |
| Clorotrianisene |
| Clorotrianisene [DCIT] |
| Clorotrianiseno |
| Clorotrianiseno [INN-Spanish] |
| Clorotrisin |
| D00269 |
| D0X0KJ |
| DB00269 |
| DSSTox_CID_1299 |
| DSSTox_GSID_21299 |
| DSSTox_RID_76067 |
| DTXSID1021299 |
| EINECS 209-318-6 |
| Ethylene, chlorotris(p-methoxyphenyl)- |
| FT-0632409 |
| GTPL7146 |
| HMS1570G16 |
| HMS1920K17 |
| HMS2091C20 |
| HMS2097G16 |
| HMS2230L03 |
| HMS3371E11 |
| Hormonisene |
| HSDB 3302 |
| KBio2_000596 |
| KBio2_003164 |
| KBio2_005732 |
| KBio3_001225 |
| KBioGR_001568 |
| KBioSS_000596 |
| Khlortrianizen |
| LS-226 |
| Merbentul |
| Metace |
| MLS000028625 |
| MLS002415722 |
| MolPort-001-783-515 |
| NCGC00016511-01 |
| NCGC00016511-02 |
| NCGC00016511-03 |
| NCGC00016511-04 |
| NCGC00016511-05 |
| NCGC00016511-08 |
| NCGC00091333-01 |
| NCGC00091333-02 |
| NCGC00091333-03 |
| NCGC00256381-01 |
| NCGC00259910-01 |
| NSC-10108 |
| NSC10108 |
| Opera_ID_1728 |
| OR008534 |
| OR286687 |
| Prestwick_22 |
| Prestwick0_000757 |
| Prestwick1_000757 |
| Prestwick2_000757 |
| Prestwick3_000757 |
| Rianil |
| s4629 |
| SBI-0051309.P003 |
| SCHEMBL8225 |
| SMR000058658 |
| SPBio_000887 |
| SPBio_002713 |
| Spectrum_000136 |
| SPECTRUM1500181 |
| Spectrum2_000704 |
| Spectrum3_000343 |
| Spectrum4_000954 |
| Spectrum5_000711 |
| SR-01000721940 |
| SR-01000721940-2 |
| Tace (pharmaceutical) |
| TACE (TN) |
| Tace-fn |
| Tox21_110466 |
| Tox21_110466_1 |
| Tox21_202361 |
| Tox21_302897 |
| Tri-p-anisylchloroethylene |
| Triagen |
| Trianisestrol |
| Tris(p-methoxyphenyl)chloroethylene |
| UNII-6V5034L121 |
| WLN: 1OR DYGUYR DO1&R DO1 |
| ZINC1530598 |
US Patents and Regulatory Information for TACE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 008102-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 011444-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 016235-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
or, see our see our flat-rate plans
